Urbonas Gediminas, Valius Leonas, Šakalytė Gintarė, Petniūnas Kęstutis, Petniūnienė Inesa
Department of Family medicine, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.
Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, LT-50161 Kaunas, Lithuania.
Medicina (Kaunas). 2019 Jan 15;55(1):15. doi: 10.3390/medicina55010015.
Long-term therapy with oral anticoagulants is recommended for stroke prevention in patients with atrial fibrillation (AF). This study evaluated the quality of anticoagulation therapy among warfarin-treated AF patients in selected primary health care centres in Lithuania. : This was a retrospective study conducted in nine primary health care centres in Lithuania. Existing medical records of randomly selected adult patients with AF who were treated with warfarin for at least 12 months were reviewed and analysed. Physicians' decisions to adjust warfarin dose were considered as consistent with the approved warfarin posology if warfarin dose was increased in case of international normalized ratio (INR) <2.0, decreased in case of INR >3.0 or unchanged in case of INR within 2.0 to 3.0. The study population included 406 patients. The mean duration of treatment with warfarin was 5.4 years. The median number of INR measurements per patient per year was 8.0. More than half (57.3%) of available INR values were outside the target range, with 13.6% INR values being above 3.0 and 43.7% INR values-below 2.0. The median time in therapeutic range (TTR) was 40.0%; only 20% of patients had TTR of ≥65%. In about 40% of the cases with INR values outside the target range, no dose corrections were implemented. About 27% of decisions on warfarin dose adjustment were not consistent with the recommended warfarin posology. The median number of INR measurements was lower among patients living in urban areas, while the median TTR was significantly higher in urban patients than in rural patients. In the multivariate regression model, gender, HAS-BLED score and warfarin treatment duration were associated with a TTR of ≥65%. : Anticoagulation control is suboptimal in routine clinical practice with a median TTR of 40%. Our findings suggest that there might be a room for improvement of anticoagulation control in primary care.
对于心房颤动(AF)患者,推荐使用口服抗凝剂进行长期治疗以预防中风。本研究评估了立陶宛部分初级卫生保健中心接受华法林治疗的AF患者的抗凝治疗质量。:这是一项在立陶宛九个初级卫生保健中心进行的回顾性研究。对随机选择的接受华法林治疗至少12个月的成年AF患者的现有病历进行了回顾和分析。如果国际标准化比值(INR)<2.0时增加华法林剂量、INR>3.0时减少华法林剂量或INR在2.0至3.0之间时华法林剂量不变,则医生调整华法林剂量的决定被视为符合批准的华法林剂量学。研究人群包括406名患者。华法林治疗的平均持续时间为5.4年。每位患者每年INR测量的中位数为8.0。超过一半(57.3%)的可用INR值超出目标范围,其中13.6%的INR值高于3.0,43.7%的INR值低于2.0。治疗范围内的中位时间(TTR)为40.0%;只有20%的患者TTR≥65%。在约40%的INR值超出目标范围的病例中,未进行剂量校正。关于华法林剂量调整的决定中约27%不符合推荐的华法林剂量学。居住在城市地区的患者INR测量的中位数较低,而城市患者的中位TTR显著高于农村患者。在多变量回归模型中,性别、HAS - BLED评分和华法林治疗持续时间与TTR≥65%相关。:在常规临床实践中,抗凝控制不理想,中位TTR为40%。我们的研究结果表明,初级保健中的抗凝控制可能有改进空间。